Dong R, Zhang M, Hu Q, Zheng S, Soh A, Zheng Y, Yuan H (2018) Galectin-3 as a novel biomarker for disease diagnosis and a target for therapy (Review). Int J Mol Med 41(2):599–614. https://doi.org/10.3892/ijmm.2017.3311

Article  CAS  PubMed  Google Scholar 

Ho JE, Gao W, Levy D, Santhanakrishnan R, Araki T, Rosas IO, Hatabu H, Latourelle JC, Nishino M, Dupuis J, Washko GR, O’onnor GT, Hunninghake GM (2016) Galectin-3 is associated with restrictive lung disease and interstitial lung abnormalities. Am J Respir Crit Care Med 194(1):77–83. https://doi.org/10.1164/rccm.201509-1753OC

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ho JE, Liu C, Lyass A, Courchesne P, Pencina MJ, Vasan RS, Larson MG, Levy D (2012) Galectin-3, a marker of cardiac fibrosis, predicts incident heart failure in the community. J Am Coll Cardiol 60(14):1249–1256. https://doi.org/10.1016/j.jacc.2012.04.053

Article  CAS  PubMed  PubMed Central  Google Scholar 

Henderson NC, Mackinnon AC, Farnworth SL, Poirier F, Russo FP, Iredale JP, Haslett C, Simpson KJ, Sethi T (2006) Galectin-3 regulates myofibroblast activation and hepatic fibrosis. Proc Natl Acad Sci USA 103(13):5060–5065. https://doi.org/10.1073/pnas.0511167103

Article  CAS  PubMed  PubMed Central  Google Scholar 

Cervantes-Alvarez E, la Rosa NL, la Mora MS, Valdez-Sandoval P, Palacios-Jimenez M, Rodriguez-Alvarez F, Vera-Maldonado BI, Aguirre-Aguilar E, Escobar-Valderrama JM, Alanis-Mendizabal J, Mendez-Guerrero O, Tejeda-Dominguez F, Torres-Ruiz J, Gomez-Martin D, Colborn KL, Kershenobich D, Huang CA, Navarro-Alvarez N (2022) Galectin-3 as a potential prognostic biomarker of severe COVID-19 in SARS-CoV-2 infected patients. Sci Rep 12(1):1856. https://doi.org/10.1038/s41598-022-05968-4

Article  CAS  PubMed  PubMed Central  Google Scholar 

Gudowska M, Gruszewska E, Cylwik B, Panasiuk A, Rogalska M, Flisiak R, Szmitkowski M, Chrostek L (2015) Galectin-3 concentration in liver diseases. Ann Clin Lab Sci 45(6):669–673

CAS  PubMed  Google Scholar 

Mackinnon AC, Gibbons MA, Farnworth SL, Leffler H, Nilsson UJ, Delaine T, Simpson AJ, Forbes SJ, Hirani N, Gauldie J, Sethi T (2012) Regulation of transforming growth factor-beta1-driven lung fibrosis by galectin-3. Am J Respir Crit Care Med 185(5):537–546. https://doi.org/10.1164/rccm.201106-0965OC

Article  CAS  PubMed  PubMed Central  Google Scholar 

Delaine T, Collins P, MacKinnon A, Sharma G, Stegmayr J, Rajput VK, Mandal S, Cumpstey I, Larumbe A, Salameh BA, Kahl-Knutsson B, van Hattum H, van Scherpenzeel M, Pieters RJ, Sethi T, Schambye H, Oredsson S, Leffler H, Blanchard H, Nilsson UJ (2016) Galectin-3-binding glycomimetics that strongly reduce bleomycin-induced lung fibrosis and modulate intracellular glycan recognition. ChemBioChem 17(18):1759–1770. https://doi.org/10.1002/cbic.201600285

Article  CAS  PubMed  Google Scholar 

Zetterberg FR, MacKinnon A, Brimert T, Gravelle L, Johnsson RE, Kahl-Knutson B, Leffler H, Nilsson UJ, Pedersen A, Peterson K, Roper JA, Schambye H, Slack RJ, Tantawi S (2022) Discovery and optimization of the first highly effective and orally available galectin-3 inhibitors for treatment of fibrotic disease. J Med Chem 65(19):12626–12638. https://doi.org/10.1021/acs.jmedchem.2c00660

Article  CAS  PubMed  PubMed Central  Google Scholar 

Farhad M, Rolig AS, Redmond WL (2018) The role of Galectin-3 in modulating tumor growth and immunosuppression within the tumor microenvironment. Oncoimmunology 7(6):e1434467. https://doi.org/10.1080/2162402X.2018.1434467

Article  PubMed  PubMed Central  Google Scholar 

Vuong L, Kouverianou E, Rooney CM, McHugh BJ, Howie SEM, Gregory CD, Forbes SJ, Henderson NC, Zetterberg FR, Nilsson UJ, Leffler H, Ford P, Pedersen A, Gravelle L, Tantawi S, Schambye H, Sethi T, MacKinnon AC (2019) An orally active galectin-3 antagonist inhibits lung adenocarcinoma growth and augments response to PD-L1 blockade. Cancer Res 79(7):1480–1492. https://doi.org/10.1158/0008-5472.CAN-18-2244

Article  CAS  PubMed  Google Scholar 

Capalbo C, Scafetta G, Filetti M, Marchetti P, Bartolazzi A (2019) Predictive biomarkers for checkpoint inhibitor-based immunotherapy: The galectin-3 signature in NSCLCs. Int J Mol Sci. https://doi.org/10.3390/ijms20071607

Article  PubMed  PubMed Central  Google Scholar 

Mabbitt J, Holyer ID, Roper JA, Nilsson UJ, Zetterberg FR, Vuong L, Mackinnon AC, Pedersen A, Slack RJ (2023) Resistance to anti-PD-1/anti-PD-L1: galectin-3 inhibition with GB1211 reverses galectin-3-induced blockade of pembrolizumab and atezolizumab binding to PD-1/PD-L1. Front Immunol 14:1250559. https://doi.org/10.3389/fimmu.2023.1250559

Article  CAS  PubMed  PubMed Central  Google Scholar 

Aslanis V, Slack RJ, MacKinnon AC, McClinton C, Tantawi S, Gravelle L, Nilsson UJ, Leffler H, Brooks A, Khindri SK, Marshall RP, Pedersen A, Schambye H, Zetterberg F (2023) Safety and pharmacokinetics of GB1211, an oral galectin-3 inhibitor: a single- and multiple-dose first-in-human study in healthy participants. Cancer Chemother Pharmacol 91(3):267–280. https://doi.org/10.1007/s00280-023-04513-y

Article  CAS  PubMed  PubMed Central  Google Scholar 

MacKenzie-Smith L, Marchi P, Thorne H, Timeus S, Young R, Le Calve P (2018) Patient preference and physician perceptions of patient preference for oral pharmaceutical formulations: results from a real-life survey. Inflamm Intest Dis 3(1):43–51. https://doi.org/10.1159/000493346

Article  PubMed  PubMed Central  Google Scholar 

Stewart KD, Johnston JA, Matza LS, Curtis SE, Havel HA, Sweetana SA, Gelhorn HL (2016) Preference for pharmaceutical formulation and treatment process attributes. Patient Prefer Adherence 10:1385–1399. https://doi.org/10.2147/PPA.S101821

Article  PubMed  PubMed Central  Google Scholar 

U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER) (2002) Food-effect bioavailability and fed bioequivalence studies. https://www.fda.gov/files/drugs/published/Food-Effect-Bioavailability-and-Fed-Bioequivalence-Studies.pdf. Accessed June 19, 2024

European Medicines Agency (EMA) (2022) ICH guideline M10 on bioanalytical method validation and study sample analysis step 5. https://www.ema.europa.eu/en/documents/scientific-guideline/ich-guideline-m10-bioanalytical-method-validation-step-5_en.pdf. Accessed June 17, 2024

Tugues S, Burkhard SH, Ohs I, Vrohlings M, Nussbaum K, Vom Berg J, Kulig P, Becher B (2015) New insights into IL-12-mediated tumor suppression. Cell Death Differ 22(2):237–246. https://doi.org/10.1038/cdd.2014.134

Article  CAS  PubMed  Google Scholar 

Malireddi RKS, Karki R, Sundaram B, Kancharana B, Lee S, Samir P, Kanneganti TD (2021) Inflammatory cell death, PANoptosis, mediated by cytokines in diverse cancer lineages inhibits tumor growth. Immunohorizons 5(7):568–580. https://doi.org/10.4049/immunohorizons.2100059

Article  CAS  PubMed  Google Scholar 

Penaloza HF, Noguera LP, Riedel CA, Bueno SM (2018) Expanding the current knowledge about the role of interleukin-10 to major concerning bacteria. Front Microbiol 9:2047. https://doi.org/10.3389/fmicb.2018.02047

Article  PubMed  PubMed Central  Google Scholar 

Midiri A, Mancuso G, Beninati C, Gerace E, Biondo C (2021) The relevance of IL-1-signaling in the protection against gram-positive bacteria. Pathogens. https://doi.org/10.3390/pathogens10020132

Article  PubMed  PubMed Central  Google Scholar